Distinct modulation of voltage‐gated and ligand‐gated Ca2+ currents by PPAR‐γ agonists in cultured hippocampal neurons
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Type 2 diabetes mellitus is a metabolic disorder characterized by hyperglycemia and is especially prevalent in the elderly. Because aging is a risk factor for type 2 diabetes mellitus, and insulin resistance may contribute to the pathogenesis of Alzheimer’s disease (AD), anti‐diabetic agents (thiazolidinediones‐TZDs) are being studied for the treatment of cognitive decline associated with AD. These agents normalize insulin sensitivity in the periphery and can improve cognition and verbal memory in AD patients. Based on evidence that Ca 2+ dysregulation is a pathogenic factor of brain aging/AD, we tested the hypothesis that TZDs could impact Ca 2+ signaling/homeostasis in neurons. We assessed the effects of pioglitazone and rosiglitazone (TZDs) on two major sources of Ca 2+ influx in primary hippocampal cultured neurons, voltage‐gated Ca 2+ channel (VGCC) and the NMDA receptor (NMDAR). VGCC‐ and NMDAR‐mediated Ca 2+ currents were recorded using patch‐clamp techniques, and Ca 2+ intracellular levels were monitored with Ca 2+ imaging techniques. Rosiglitazone, but not pioglitazone reduced VGCC currents. In contrast, NMDAR‐mediated currents were significantly reduced by pioglitazone but not rosiglitazone. These results show that TZDs modulate Ca 2+‐dependent pathways in the brain and have different inhibitory profiles on two major Ca 2+ sources, potentially conferring neuroprotection to an area of the brain that is particularly vulnerable to the effects of aging and/or AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The mechanisms of action of PPARs
Berger, J., & Moller, D. E. (2002) · Annual Review of Medicine · doi:10.1146/annurev.med.53.082901.104018 · Cited by 2,659
Risk of dementia in diabetes mellitus: a systematic review
Biessels, G. J., Staekenborg, S., Brunner, E., Brayne, C., & Scheltens, P. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(05)70284-2 · Cited by 2,187
Memantine in Moderate-to-Severe Alzheimer's Disease
Reisberg, B., Doody, R., Stöffler, A., Schmitt, F., Ferris, S., & Möbius, H. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa013128 · Cited by 2,043
Steen, E., Terry, B. M., J. Rivera, E., Cannon, J. L., Neely, T. R., Tavares, R., Xu, X. J., Wands, J. R., & de la Monte, S. M. (2005) · Journal of Alzheimer's Disease · doi:10.3233/jad-2005-7107 · Cited by 1,703 · cited 2×
“Furthermore, insulin resistance associated with type 2 diabetes mellitus (T2DM) may be an important pathogenic factor in AD (Watson and Craft 2003; Steen et al. 2005; Li and Holscher 2007), and thought to be present in 80% of the AD population (Janson et al. 2004).”
BackgroundSchoonjans, K., Peinado‐Onsurbe, J., Lefebvre, A. M., Heyman, R. A., Briggs, M., Deeb, S., Staels, B., & Auwerx, J. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00918.x · Cited by 1,173
Increased Risk of Type 2 Diabetes in Alzheimer Disease
Janson, J., Laedtke, T., Parisi, J. E., O’Brien, P., Petersen, R. C., & Butler, P. C. (2004) · Diabetes · doi:10.2337/diabetes.53.2.474 · Cited by 950 · cited 2×
“Furthermore, insulin resistance associated with type 2 diabetes mellitus (T2DM) may be an important pathogenic factor in AD (Watson and Craft 2003; Steen et al. 2005; Li and Holscher 2007), and thought to be present in 80% of the AD population (Janson et al. 2004).”
BackgroundForette, F. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.18.2046 · Cited by 898 · cited 4×
“1992; Kowalska and Disterhoft 1994), and can reduce risk of dementia in hypertensive or AD patients (Forette et al. 2002; Reisberg et al. 2003; Lipton 2004), we sought to test the hypothesis that TZDs could reduce Ca signaling in neurons.”
BackgroundInfluentialRisner, M. E., Saunders, A. M., Altman, J. F. B., Ormandy, G. C., Craft, S., Foley, I. M., Zvartau-Hind, M. E., Hosford, D. A., Roses, A. D., & for the Rosiglitazone in Alzheimer's Disease Study Group (2006) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500369 · Cited by 686
Heneka, M. T., Sastre, M., Dumitrescu-Ozimek, L., Hanke, A., Dewachter, I., Kuiperi, C., O'Banion, K., Klockgether, T., Van Leuven, F., & Landreth, G. E. (2005) · Brain · doi:10.1093/brain/awh452 · Cited by 565
Martin, G., Schoonjans, K., Lefebvre, A.-M., Staels, B., & Auwerx, J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.45.28210 · Cited by 551 · cited 1×
“In adipocytes, TZDs promote lipid accumulation by increasing gene transcription for several fatty acid binding proteins (Schoonjans et al. 1996; Martin et al. 1997; Berger and Moller 2002).”
Background
Cited by
Diabetes mellitus and Alzheimer's disease: shared pathology and treatment?
Akter, K., Lanza, E. A., Martin, S. A., Myronyuk, N., Rua, M., & Raffa, R. B. (2011) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2010.03830.x · Cited by 352
Searcy, J. L., Phelps, J. T., Pancani, T., Kadish, I., Popovic, J., Anderson, K. L., Beckett, T. L., Murphy, M. P., Chen, K.-C., Blalock, E. M., et al. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-111661 · Cited by 154
Self-citationKemp, D. E., Ismail-Beigi, F., Ganocy, S. J., Conroy, C., Gao, K., Obral, S., Fein, E., Findling, R. L., & Calabrese, J. R. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.06.033 · Cited by 109
Sinagra, T., Tamburella, A., Urso, V., Siarkos, I., Drago, F., Bucolo, C., & Salomone, S. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.11.013 · Cited by 18
Metadata
- Authors
- Pancani, T., Phelps, J. T., Searcy, J. L., Kilgore, M. W., Chen, K., Porter, N. M., & Thibault, O.
- Venue
- Journal of Neurochemistry
- Publisher
- Wiley
- Published
- 2009-05-21
- Volume
- 109
- Issue
- 6
- Pages
- 1800-1811
- ISSN
- 0022-3042 (ISSN-L)
- 1471-4159
- OpenAlex
- W2059382506
- Cited by
- 75
- References
- 19
- FWCI
- 2.89
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Distinct modulation of voltage‐gated and ligand‐gated Ca2+ currents by PPAR‐γ agonists in cultured hippocampal neurons. https://app.cochat.ai/papers/10.1111/j.1471-4159.2009.06107.x
- The paper
- Pancani, T., Phelps, J. T., Searcy, J. L., Kilgore, M. W., Chen, K., Porter, N. M., & Thibault, O. (2009). Distinct modulation of voltage‐gated and ligand‐gated Ca2+ currents by PPAR‐γ agonists in cultured hippocampal neurons. Journal of Neurochemistry. https://doi.org/10.1111/j.1471-4159.2009.06107.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.